CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.61B, above the global median of $1.18B
- PositionReturn on equity is -255.9%, lower than 95% of its Biotechnology peers (median -23.6%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.61BUSDvs all stocks (USD)
Revenue (TTM)
252.25MUSDvs all stocks (USD)
Profit Margin
-87.52%vs Biotechnology peers
Beta
0.3710xvs all stocks
52-Week Change
13.69%vs all stocks
Market Capitalization
1.61BUSDvs all stocks (USD)
Enterprise Value
1.66BUSDvs all stocks (USD)
Forward P/E
-22.31xvs Biotechnology peers
Price to Sales (TTM)
6.39xvs Biotechnology peers
Price to Book (MRQ)
107.69xvs Biotechnology peers
Enterprise to Revenue
6.58xvs Biotechnology peers
Enterprise to EBITDA
-8.55xvs Biotechnology peers
Gross Margin
95.59%vs Biotechnology peers
Profit Margin
-87.52%vs Biotechnology peers
Operating Margin
-54.95%vs Biotechnology peers
Return on Assets (TTM)
-18.67%vs Biotechnology peers
Return on Equity (TTM)
-255.93%vs Biotechnology peers
Revenue (TTM)
252.25MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.87USDUpdated Sep 28, 2026Quarterly Revenue Growth
91.80%vs Biotechnology peers
Gross Profit (TTM)
-20.20MUSDvs all stocks (USD)
EBITDA (TTM)
-194.16MUSDvs all stocks (USD)
Net Income (TTM)
-220.76MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
91.76%vs Biotechnology peers
Operating Cash Flow (TTM)
-220.64MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-150.08MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
172.35MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.97MUSDFY2025 · Dec 31, 2025Gross Profit
165.38MUSDFY2025 · Dec 31, 2025Operating Income
-273.08MUSDvs all stocks (USD)
Pre-tax Income
-285.42MUSDFY2025 · Dec 31, 2025Net Income
-285.42MUSDFY2025 · Dec 31, 2025EBIT
-251.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-251.63MUSDFY2025 · Dec 31, 2025Research & Development
258.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
179.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.29USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.29USDFY2025 · Dec 31, 2025Basic Shares Outstanding
86.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
86.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-285.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-343.52MUSDFY2025 · Dec 31, 2025Free Cash Flow
-343.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
135.03MUSDFY2025 · Dec 31, 2025Interest Paid
13.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-285.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
47.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.34MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-79.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-32.09MUSDFY2025 · Dec 31, 2025Capital Expenditures
-187.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-195.81MUSDFY2025 · Dec 31, 2025Sale of Investments
486.03MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
290.04MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
89.15MSharesUpdated Sep 28, 2026Float Shares
80.30MSharesUpdated Sep 28, 2026Shares Short
20.66MSharesUpdated Sep 28, 2026Short Ratio
16.22daysvs all stocks
Short % of Shares Outstanding
23.54%vs all stocks
% Held by Insiders
1.69%vs all stocks
% Held by Institutions
126.12%vs all stocks
Total Cash (MRQ)
554.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.21USDUpdated Sep 28, 2026Total Debt (MRQ)
589.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
39.03xvs Biotechnology peers
Current Ratio (MRQ)
6.77xvs Biotechnology peers
Book Value per Share (MRQ)
0.1690USDUpdated Sep 28, 2026Total Assets
529.71MUSDvs all stocks (USD)
Total Current Assets
528.08MUSDFY2025 · Dec 31, 2025Total Liabilities
465.08MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.63MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
344.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
120.12MUSDFY2025 · Dec 31, 2025Cash Equivalents
134.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
134.93MUSDFY2025 · Dec 31, 2025Other Short-term Investments
278.76MUSDFY2025 · Dec 31, 2025Accounts Receivable
38.00MUSDFY2025 · Dec 31, 2025Inventory
32.75MUSDFY2025 · Dec 31, 2025Accounts Payable
16.58MUSDFY2025 · Dec 31, 2025Short-term Debt
472.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
10.53MUSDFY2025 · Dec 31, 2025Long-term Debt
344.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.51BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
64.63MUSDvs all stocks (USD)
52-Week Low
12.99USDUpdated Sep 28, 202652-Week High
25.59USDUpdated Sep 28, 202652-Week Change
13.69%vs all stocks
Beta
0.3710xvs all stocks
50-Day MA
19.68USDUpdated Sep 28, 2026200-Day MA
20.93USDUpdated Sep 28, 2026Avg 10-Day Volume
2.17MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.58MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.51USDUpdated Sep 28, 2026Other Income / Expense
-1.28MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -255.9%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -2.56Industry median: -0.24Industry P5: -1.76Peers compared: 193
Debt-to-equity is 39.03×, higher than 95% of its Biotechnology peers (median 0.12×)Significant
Debt-to-equity: 39.03Industry median: 0.12Industry P95: 2.33Peers compared: 193
Price-to-book is 107.69×, higher than 95% of its Biotechnology peers (median 4.62×)Significant
Price-to-book: 107.692Industry median: 4.62Industry P95: 31.44Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.96Profit Margin: -0.88
Significant cash reserves alongside high leverageNotable
Cash (USD): 554,265,984Total Debt (USD): 589,382,016Debt-to-Equity: 39.03
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.77Altman Z-Score: -2.22
Financial Health
Altman Z-Score -2.22: distress zoneCritical
Altman Z-Score: -2.22
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.61B, above the global median of $1.18BNotable
Market cap (USD): 1,612,702,491Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Surrozen, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
JFrog Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC